mTOR inhibitors in cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Cell Signaling

Background:

• The mammalian target of rapamycin (mTOR) is a key regulator of cell growth and proliferation.
• mTOR functions within two distinct complexes: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2).
• mTORC1 signaling is frequently hyperactivated in various cancers due to oncogenic pathway activation.

Purpose of the Study:

• To explore the therapeutic potential of inhibiting mTORC1 signaling in cancer treatment.
• To address the limitations hindering the clinical application of mTOR inhibitors in oncology.

Main Methods:

• Review of existing literature on mTOR signaling pathways.
• Analysis of the mechanisms underlying mTORC1 hyperactivity in cancer.
• Evaluation of the challenges associated with mTOR inhibitor efficacy.

Main Results:

• mTORC1 is a common target in oncogenic signaling pathways.
• Rapamycin, a classic mTOR inhibitor, exhibits incomplete inhibition of mTOR effects.
• Complex feedback loops and the essential role of mTOR in normal physiology present significant hurdles.

Conclusions:

• Targeting mTORC1 signaling is a promising anti-cancer strategy.
• Overcoming limitations of current mTOR inhibitors is critical for therapeutic success.
• Further research is needed to develop effective mTOR-targeted cancer therapies.